肿瘤细胞治疗研究
英文原题：Prevalence and Clinical Manifestations of Cannabis Withdrawal in Hospitalized Patients With Hematological Malignancies Undergoing Bone Marrow Transplant (BMT) or Chimeric Antigen Receptor T-Cell (CAR-T) Therapy
这是一项分期未标注的注册临床试验，评估细胞治疗用于肿瘤的安全性、可行性及初步疗效。当前状态：邀请入组。计划入组 300 例。试验地点：美国 · 斯科茨代尔（共 1 个中心）。登记号：NCT07594496。
不限性别 · ≥ 18 Years
入选标准：所有因 BMT 或 CAR-T 治疗住院的成年患者。 排除标准：无法提供知情同意者。
Inclusion Criteria: * All adult patients admitted for BMT or CAR-T therapy Exclusion Criteria: * Individuals unable to provide informed consent
以上为辅助阅读译文。是否适合入组须由主治医生判断，最终以登记平台与研究者确认为准。
主要终点：Prevalence of cannabis withdrawal · Descriptive statistics will be utilized to summarize cannabis withdrawal prevalence. · Up to 1 year；Severity of withdrawal symptoms · Assessed by the Cannabis Withdrawal Scale (CWS), a self-report instrument used measures the intensity of 19 cannabis withdrawal symptoms over the last 24 hours. Each item is rated on a 10-point Likert scale where 0=not al all and 10=extremely. Items are rated twice, first for intensity of symptom and then for negative impact on daily activity. Withdrawal symptom scores range from 0 to 190, with higher scores reflecting greater intensity of withdrawal symptoms. · Daily for first 4 days of hospitalization
次要终点：Mortality Rate
患者完成问卷，研究期间审阅其病历。
本研究评估因骨髓移植（BMT）或嵌合抗原受体 T 细胞（CAR-T）治疗而住院的血液系统恶性肿瘤患者中，大麻戒断的发生率及戒断综合征的临床表现。
This study evaluates the prevalence of cannabis withdrawal and the clinical manifestations of cannabis withdrawal syndrome in patients hospitalized for BMT or CAR-T therapy.
MEMBER ACCOUNT
登录成功会直接打开下一页。
